Discovery of 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a tubulin polymerization inhibitor with potent antiproliferative and tumor vascular disrupting properties

Bernard Flynn, Gill Gurmit, Damian Grobelny, Jason Chaplin, Dharam Paul, Annabell Leske, Tina Lavranos, David Chalmers, Susan Charman, Edmund Kostewicz, David Shackleford, Julia Morizzi, Ernest Hamel, Katherine Jung, Gabriel Kremmidiotis

Research output: Contribution to journalArticleResearchpeer-review

107 Citations (Scopus)

Abstract

A structure activity relationship (SAR) guided design of novel tubulin polymerization inhibitors has resulted in a series of benzo[b]furans with exceptional potency toward cancer cells and activated endothelial cells. The potency of early lead compounds has been substantially improved through the synergistic effect of introducing a conformational bias and additional hydrogen bond donor to the pharmacophore. Screening of a focused library of potent tubulin polymerization inhibitors for selectivity against cancer cells and activated endothelial cells over quiescent endothelial cells has afforded 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo-[b]furan (BNC105, 8) as a potent and selective antiproliferative. Because of poor solubility, 8 is administered as its disodium phosphate ester prodrug 9 (BNC105P), which is rapidly cleaved in vivo to return the active 8. 9 exhibits both superior vascular disrupting and tumor growth inhibitory properties compared with the benchmark agent combretastatin A-4 disodium phosphate 5 (CA4P).
Original languageEnglish
Pages (from-to)6014 - 6027
Number of pages14
JournalJournal of Medicinal Chemistry
Volume54
Issue number17
DOIs
Publication statusPublished - 2011

Cite this